CAS NO: | 140674-76-6 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
Cas No. | 140674-76-6 |
别名 | NSC 654705,Tyrphostin AG957 |
化学名 | 4-[[(2,5-dihydroxyphenyl)methyl]amino]-benzoic acid, methyl ester |
Canonical SMILES | OC1=C(CNC2=CC=C(C(OC)=O)C=C2)C=C(O)C=C1 |
分子式 | C15H15NO4 |
分子量 | 273.3 |
溶解度 | ≤5mg/ml in DMSO |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
半岛bd体育手机客户端 描述 | AG957 is a tyrosine phosphorylation inhibitor that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl), as well as normal c-Abl [1]. The abl proto-oncogene is expressed in all cell types. The protein p140c-abl is localized both to the nucleus and the cytoplasm. The abl transforming proteins p160gag-abl, p210bcr-abl, and p185bcr-abl are exclusively cytoplasmic proteins. The intrinsic protein tyrosine kinase activity of the transforming abl proteins is higher than that of the normal p140c-abl [1]. AG957 is a tyrosine phosphorylation inhibitor. AG957 inhibited human p185Bcr-Abl, p210Bcr-Abl and normal c-Abl with IC50 values of 4.3, 1, and 7.1 μM, respectively. AG957 inhibited mouse normal c-Abl with IC50 value of 6 μM. AG957 also inhibited epidermal growth factor receptor with IC50 value of 0.25 μM. In chronic myelogenous leukemia (CML) K562 cells, AG957 inhibited p210bcr-abl kinase activity and cell growth. AG957 at 20 μM also inhibited DNA synthesis as early as 2 h by 60% [2]. In K562 cells, AG957, a selective Bcr-Abl inhibitor, blocked taxol-induced PKCi activation and sensitized these cells to taxol-induced apoptosis [3]. In mice, AG957, the c-Abl inhibitor, attenuated LPS-induced pulmonary permeability [4]. References: |